Get Premium to unlock powerful stock data

Parnassus Comments on Biogen

Guru stock highlight

Author's Avatar
Sydnee Gatewood
Aug 02, 2021

Summary

  • The stock was a top contributor.
Article's Main Image

Biopharmaceutical company Biogen (

BIIB, Financial) added 61 basis points to the Fund’s return, as its stock surged from $279.75 to $346.27, for a total return of 23.8%. Biogen develops drugs that treat neurological and neurogenerative disease, including multiple sclerosis and spinal muscular atrophy. The stock soared 40% after the FDA approved Biogen’s experimental Alzheimer’s treatment. More than one hundred other Alzheimer’s drugs have failed in clinical trials over the past 20 years, so the decision is as historic as it is controversial. Investors cheered the breakthrough, which offered new hope to patients and opened a large new frontier for the company.

From the

Parnassus Endeavor Fund (Trades, Portfolio)'s second-quarter 2021 commentary.

Also check out:
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.

Disclosures

I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.
The views of this author are solely their own opinion and are not endorsed or guaranteed by GuruFocus.com
Rating:
0 / 5 (0 votes)

Please Login to leave a comment